These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Insulin--binding antibodies in Nigerian diabetic patients. Bella AF; Adetuyibi A West Afr J Med; 1990; 9(4):291-4. PubMed ID: 2083207 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody. Lam HC; Ho LT; Tang KT; Wang LM; Kwok CF; Liu YF; Hsiao LJ; Li SH Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):346-51. PubMed ID: 2677227 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of human monocomponent insulin with beef and pork monocomponent insulin in the treatment of a diabetic with insulin resistance]. Wu W; Nolte M; Karam J Zhonghua Nei Ke Za Zhi; 1987 Nov; 26(11):644-5, 677. PubMed ID: 3327662 [No Abstract] [Full Text] [Related]
8. Total IgG and IgG subclass specific antibody responses to insulin in diabetic patients. Soto-Aguilar MC; deShazo RD; Morgan JE; Mather P; Ibrahim G; Frentz JM; Lauritano AA Ann Allergy; 1991 Nov; 67(5):499-503. PubMed ID: 1958003 [TBL] [Abstract][Full Text] [Related]
9. Prolonged action of regular insulin in diabetic patients: lack of relationship to circulating insulin antibodies. Gardner DF; Wilson HK; Podet EJ; Arakaki RF; Nell LJ; Thomas JW; Crane MM; Field JB J Clin Endocrinol Metab; 1986 Apr; 62(4):621-7. PubMed ID: 3512590 [TBL] [Abstract][Full Text] [Related]
10. Insulin autoantibodies at the clinical manifestation of type 1 (insulin-dependent) diabetes--a poor predictor of clinical course and antibody response to exogenous insulin. Karjalainen J; Knip M; Mustonen A; Akerblom HK Diabetologia; 1988 Mar; 31(3):129-33. PubMed ID: 3286339 [TBL] [Abstract][Full Text] [Related]
11. Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes. Hattori N; Duhita MR; Mukai A; Matsueda M; Shimatsu A Clin Chim Acta; 2014 Jun; 433():135-8. PubMed ID: 24642342 [TBL] [Abstract][Full Text] [Related]
12. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Turner R; Stratton I; Horton V; Manley S; Zimmet P; Mackay IR; Shattock M; Bottazzo GF; Holman R Lancet; 1997 Nov; 350(9087):1288-93. PubMed ID: 9357409 [TBL] [Abstract][Full Text] [Related]
13. Immunological insulin resistance due to insulin antibodies developed after cessation of insulin therapy in a patient with type 2 diabetes. Hirano M; Arima H; Oiso Y Diabetes Care; 2008 Nov; 31(11):e84. PubMed ID: 18955711 [No Abstract] [Full Text] [Related]
14. Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission. Ludvigsson J Diabetologia; 1984 Feb; 26(2):138-41. PubMed ID: 6370760 [TBL] [Abstract][Full Text] [Related]
15. A case of a non-insulin dependent diabetic patient with regular spontaneous hypoglycemic attacks, which were due to insulin-binding antibodies induced by human insulin therapy. Suzuki K; Hirayama S; Ito S Tohoku J Exp Med; 1997 Jun; 182(2):163-73. PubMed ID: 9261935 [TBL] [Abstract][Full Text] [Related]
16. Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibody-binding kinetics. Van Haeften TW; Krom BA; Gerich JE Diabetes Care; 1987; 10(2):160-3. PubMed ID: 3582076 [TBL] [Abstract][Full Text] [Related]
17. Islet cell and insulin autoantibodies in organ-specific autoimmune patients. Their behaviour and predictive value for the development of type 1 (insulin-dependent) diabetes mellitus. A 10-year follow-up study. Betterle C; Presotto F; Pedini B; Moro L; Slack RS; Zanette F; Zanchetta R Diabetologia; 1987 May; 30(5):292-7. PubMed ID: 3301480 [TBL] [Abstract][Full Text] [Related]
18. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Zavala AV; Fabiano de Bruno LE; Cardoso AI; Mota AH; Capucchio M; Poskus E; Fainboim L; Basabe JC Diabetologia; 1992 Dec; 35(12):1159-64. PubMed ID: 1478368 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665 [TBL] [Abstract][Full Text] [Related]
20. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. Fineberg SE; Kawabata T; Finco-Kent D; Liu C; Krasner A J Clin Endocrinol Metab; 2005 Jun; 90(6):3287-94. PubMed ID: 15741258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]